Publication at First Faculty of Medicine |
2020
Abstract
Prostate cancer is the most common male malignant neoplasm in men worldwide and second cause of cancer related death. During the last decade, the treatment of metastatic castration resistant prostate cancer has dramatically changed with the approval of new agents as cabazitaxel, enzalutamide, abiraterone and radium 223.
These new therapeutic options have provided an overall survival increase from 14-18 months to average of 30-36 months. The problem is the absence of the clearly defined predictive marker.
In this review we discussing to choose the optimal treatment sequence of this disease.